On-body Injector Market Size & Share 2026-2035

On-body Injector Market Size

The global on-body injector market was valued at USD 1.2 billion in 2025 and is projected to grow from USD 1.3 billion in 2026 to USD 5.2 billion by 2035, expanding at a CAGR of 16.4%, according to the latest report published by Global Market Insights Inc. This substantial growth is driven by several key factors, including a growing incidence of chronic conditions, a shift towards home-based healthcare, and increasing demand for biologics.

An on-body injector is a wearable drug delivery device designed to administer medications subcutaneously over a specified period after being attached to the patient's body. These devices enable the delivery of large-volume biologics and specialty drugs outside traditional healthcare settings, improving treatment convenience and adherence. On-body injectors are commonly used in the management of chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions, supporting both home-based and outpatient care.

Leading companies in the on-body injector industry include Amgen Inc., West Pharmaceutical Services, Inc., Enable Injections, Inc., Ypsomed Holding AG, and Becton, Dickinson and Company (BD). These companies are strengthening their market presence through continuous innovation in large-volume subcutaneous drug delivery systems, wearable injection technologies, and patient-centric administration solutions.

The rising prevalence of chronic diseases is a significant driver of the market. Chronic conditions such as cancer, diabetes, autoimmune disorders, and cardiovascular diseases often require frequent administration of biologic drugs and long-term therapies, creating a growing need for convenient and efficient drug delivery solutions. On-body injectors enable patients to self-administer large-volume medications outside clinical settings, improving treatment adherence while reducing hospital visits. Cancer, in particular, is contributing substantially to market growth. According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, accounting for nearly 10 million deaths in 2024, representing almost one in every six deaths worldwide. Lung, breast, colorectal, and prostate cancers are among the most commonly diagnosed cancers. The increasing number of cancer patients has led to higher demand for biologics and targeted therapies that often require subcutaneous administration. On-body injectors provide a patient-friendly method for delivering these therapies accurately and comfortably. As the global burden of chronic diseases continues to rise and healthcare systems increasingly emphasize home-based care, the adoption of on-body injectors is expected to accelerate, supporting sustained market expansion.

Additionally, the growing shift toward home-based healthcare is a key driver of the on-body injector industry. Healthcare systems worldwide are increasingly promoting care delivery outside traditional hospital settings to reduce healthcare costs, improve patient convenience, and alleviate the burden on medical facilities. Patients with chronic conditions, including cancer, autoimmune diseases, and diabetes, often require frequent and long-term drug administration, making home-based treatment an attractive alternative to repeated clinic visits. On-body injectors support this transition by enabling safe, accurate, and convenient self-administration of large-volume biologic medications at home. These devices are designed to enhance patient comfort and independence while ensuring precise drug delivery. Their user-friendly features reduce the need for healthcare professional supervision and help improve treatment adherence, particularly among elderly patients and those with mobility limitations. Additionally, advancements in digital health technologies and remote patient monitoring have strengthened confidence in home-based care models, allowing healthcare providers to track treatment outcomes effectively. As patients increasingly seek flexible and convenient treatment options and healthcare providers focus on decentralized care delivery, demand for on-body injectors is expected to rise significantly, driving market growth over the coming years.

On-body Injector Market Trends

• The increasing demand for biologics is a major factor supporting the growth of the market. Biologics are increasingly being used for the treatment of chronic conditions such as cancer, autoimmune disorders, and cardiovascular diseases due to their targeted therapeutic benefits. This has created a growing need for efficient drug delivery solutions capable of administering complex formulations.
• Additionally, many biologic drugs require large-volume subcutaneous administration, which can be challenging with conventional injection methods. On-body injectors address this challenge by enabling controlled and convenient delivery over a predetermined period. Their ability to support patient-friendly administration is contributing to wider adoption.
• Furthermore, pharmaceutical companies are expanding their biologics pipelines and increasing investments in the development of advanced specialty therapeutics. As the number of biologic drug approvals continues to rise, demand for compatible delivery platforms is also increasing. This trend is creating significant growth opportunities for on-body injector manufacturers.
• Moreover, the growing preference for home-based treatment and self-administration is further accelerating adoption. On-body injectors allow patients to receive biologic therapies outside clinical settings while maintaining treatment continuity and adherence. As biologics become an increasingly important component of modern healthcare, demand for on-body injectors is expected to grow steadily.

On-body Injector Market Analysis

Based on device type, the on-body injector market is bifurcated into programmable wearable injectors and non-programmable wearable injectors. The programmable wearable injectors segment dominated the market with the largest revenue share of 58.8% in 2025.

• Programmable wearable injectors have gained strong traction as healthcare providers increasingly focus on personalized treatment approaches and precise drug administration. These devices allow adjustment of delivery rates, timing, and dosage parameters, making them suitable for complex biologic therapies that require controlled administration.
• Their adoption continues to expand across chronic disease management, particularly in oncology and autoimmune disorders, where treatment accuracy is critical. Advancements in connected healthcare technologies and smart drug delivery systems have further strengthened the integration of programmable injectors into modern patient care pathways.
• The non-programmable wearable injectors segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 16% over the forecast period. Non-programmable wearable injectors remain an important segment due to their simplicity, ease of use, and cost-effectiveness. These devices are designed to deliver fixed doses with minimal user intervention, making them well-suited for routine therapies and standardized treatment regimens.
• Growing emphasis on self-administration and patient convenience has supported the uptake of non-programmable injectors across various healthcare settings. Their straightforward design also contributes to broader accessibility, particularly in regions seeking affordable drug delivery solutions.

Based on usage type, the on-body injector market is categorized into disposable wearable injectors and reusable wearable injectors. The disposable wearable injectors segment dominated the market with the largest revenue share of 76.8% in 2025.

• Disposable wearable injectors are widely utilized in situations where convenience and hygiene are critical considerations. Their single-use format removes the need for maintenance, cleaning, or device retrieval following treatment. This simplifies the overall administration process and supports efficient therapy delivery. Such advantages have made them a preferred option for many biologic treatments.
• The growing movement toward self-administration and home-based healthcare is creating favorable conditions for adoption. Pharmaceutical companies increasingly package therapies with ready-to-use delivery systems to enhance patient experience. Demand is also benefiting from the need to reduce contamination risks during medication administration. These factors continue to support market expansion for disposable devices.
• The reusable segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 17.1% over the forecast period. Reusable wearable injectors are gaining traction as healthcare providers focus on long-term treatment efficiency and resource optimization. Their ability to be used across multiple treatment cycles makes them attractive for chronic disease management. The segment is increasingly associated with sustainability initiatives aimed at reducing medical device waste. This positions reusable systems as a viable alternative in several healthcare settings.
• Manufacturers are introducing durable and patient-friendly platforms capable of supporting repeated use without compromising performance. Such developments are improving confidence among healthcare providers and end users. Interest is particularly evident in therapies requiring frequent administration over many years. As a result, reusable injectors are gradually strengthening their presence within the market.

Based on technology, the on-body injector market is segmented into motor-driven, spring-based, expanding battery, rotary pump, and other technologies. The spring-based segment dominated the market with the largest revenue share of 39.4% in 2025.

• Spring-based on-body injectors remain an important technology segment due to their mechanical simplicity and dependable operational performance. The technology enables efficient drug administration without extensive reliance on electronic systems. Its compact design and ease of handling contribute to broad acceptance among users. This has sustained demand across multiple healthcare environments.
• Growing emphasis on convenient and user-friendly treatment solutions continues to support adoption. Manufacturers are enhancing device ergonomics and delivery performance to improve patient experience. The segment also benefits from its established presence in drug delivery applications. These advantages continue to support steady market development.
• The motor-driven segment is anticipated to grow at a CAGR of 16.4% over the forecast period. Motor-driven technology is widely recognized for its ability to deliver medications with precise flow control and dosing accuracy. These capabilities are particularly important for advanced biologics and large-volume drug formulations. The technology is increasingly being utilized in therapies where consistency and reliability are essential. Its versatility supports application across multiple therapeutic areas.
• Continuous advancements in device engineering have improved system performance and operational efficiency. Pharmaceutical manufacturers are increasingly aligning products with delivery platforms that can accommodate complex formulations. This has resulted in broader acceptance of motor-driven solutions within the wearable injector landscape. Their importance is expected to grow alongside innovation in injectable therapeutics.
• The expanding battery segment is anticipated to grow at a CAGR of 16% over the forecast period. Expanding battery technology is emerging as a promising area within the on-body injector market, driven by the need for compact and efficient drug delivery systems. The technology supports controlled administration while enabling lightweight product designs. Increasing focus on patient comfort and portability is generating greater interest in this category. This is encouraging continued product development activity.
• Manufacturers are investing in advanced battery technologies to improve operational performance and energy efficiency. Ongoing innovations are supporting the development of next-generation on-body injectors with enhanced functionality. The segment is also benefiting from increasing research focused on miniaturized delivery systems. These trends are expected to create favorable growth opportunities.
• The rotary pump segment is anticipated to grow at a CAGR of 17% over the forecast period. Rotary pump technology is attracting growing attention due to its capability to support controlled fluid movement and precise medication administration. Its operational flexibility allows effective handling of different drug formulations and therapeutic requirements. Such characteristics make the technology increasingly relevant within advanced injectable therapies. This is contributing to rising industry interest.
• The expansion of specialty drug pipelines is creating demand for sophisticated delivery mechanisms capable of ensuring dosing consistency. Rotary pump-based on-body injectors are well positioned to address these requirements. Continued investment in technology development is further improving performance capabilities. As a result, the segment is steadily gaining market relevance.

Based on application, the on-body injector market is segmented into oncology, cardiovascular disease, diabetes, autoimmune disease, infectious disease, and other applications. The oncology segment dominated the market with the largest revenue share of 34.5% in 2025.

• Oncology represents the largest application segment due to the increasing use of biologics, targeted therapies, and immunotherapies in cancer treatment. Many oncology treatments require repeated administration over extended periods, creating strong demand for efficient drug delivery solutions. On-body injectors help improve treatment accessibility while supporting continuity of care. This has strengthened their role within oncology treatment pathways.
• Rising global cancer incidence continues to increase the number of patients requiring long-term therapeutic management. Healthcare providers are seeking solutions that enhance convenience and reduce reliance on traditional infusion settings. On-body injectors align well with these requirements by offering greater treatment flexibility.
• The cardiovascular disease segment is anticipated to grow at a CAGR of 16.9% over the forecast period. The cardiovascular disease segment is expanding as healthcare systems place greater emphasis on long-term disease management and treatment adherence. Patients often require ongoing administration of specialized therapies, creating demand for convenient delivery options. On-body injectors support these treatment requirements by simplifying drug administration processes. This is contributing to their increasing utilization.
• Growing prevalence of cardiovascular disorders worldwide is generating higher demand for advanced treatment solutions. For instance, according to the World Health Organization (WHO), cardiovascular diseases (CVDs) caused an estimated 19.8 million deaths in 2022, accounting for approximately 32% of all deaths globally. Of these fatalities, around 85% resulted from heart attacks and strokes. Healthcare providers are increasingly focusing on approaches that improve patient engagement and therapy compliance. On-body injectors help address these objectives while supporting effective medication delivery. These factors continue to drive segment growth.
• The autoimmune disease segment is anticipated to grow at a CAGR of 16% over the forecast period. Autoimmune diseases represent a significant application area owing to the widespread use of biologic therapies for disease management. Patients frequently require regular medication administration over extended periods, creating favorable conditions for the adoption of on-body injectors. The technology offers a convenient approach to managing recurring treatment requirements while reducing dependence on frequent healthcare facility visits.
• For instance, according to Johns Hopkins Medicine, autoimmune diseases collectively affect approximately 3% of the U.S. population, equivalent to nearly 10 million people. The substantial patient population requiring long-term therapy has increased the importance of reliable and patient-friendly drug delivery systems. On-body injectors support treatment continuity by enabling convenient administration in non-clinical settings, helping improve adherence and overall treatment experience. As a result, their utilization across autoimmune disease management continues to expand steadily.
• The infectious disease segment is anticipated to grow at a CAGR of 17.2% over the forecast period. The infectious disease segment is benefiting from advancements in specialty therapeutics and evolving treatment approaches. Increasing focus on efficient and accessible drug administration is creating opportunities for the adoption of on-body injectors. These systems provide flexibility in treatment delivery across various healthcare settings. This is supporting gradual market expansion.
• Healthcare providers are increasingly implementing decentralized care models that enhance patient access to therapies. On-body injectors complement these initiatives by enabling more convenient medication administration. The introduction of innovative infectious disease treatments is further supporting utilization. Together, these factors contribute to segment growth.

Based on end use, the on-body injector market is segmented into hospitals, homecare settings, and specialty clinics & ambulatory surgery centers. The homecare settings segment dominated the market with the largest revenue share of 46.2% in 2025.

• Homecare settings are emerging as one of the fastest-growing end-use segments as healthcare delivery increasingly shifts toward patient-centric models. On-body injectors enable therapy administration outside conventional healthcare facilities while maintaining treatment continuity. This flexibility is becoming increasingly important for patients managing chronic conditions. As a result, adoption continues to accelerate.
• The expansion of self-administration practices and remote patient monitoring programs is further supporting demand. Healthcare providers and payers are promoting home-based treatment models to improve convenience and reduce overall healthcare burden. On-body injectors align closely with these changing care preferences. This is driving sustained market growth.
• The hospitals segment was valued at USD 499.2 million in 2025 and is anticipated to grow at a CAGR of 16.2% over the forecast period. Hospitals account for a significant share of the market as they remain primary centers for administering complex therapies and specialized treatments. Many biologics and high-value pharmaceutical products are initiated within hospital settings, supporting sustained demand for on-body injectors. Their integration into treatment pathways helps improve efficiency and patient management. This continues to support segment growth.
• Ongoing investments in advanced healthcare infrastructure are facilitating the adoption of innovative drug delivery technologies. Hospitals frequently serve as early adopters of newly introduced therapeutic solutions. The availability of skilled healthcare professionals further supports utilization. These factors maintain the segment's importance within the market.
• The specialty clinics and ambulatory surgery centers accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 15% over the forecast period. Specialty clinics and ambulatory surgery centers are increasingly incorporating on-body injectors into outpatient treatment workflows. These facilities emphasize efficient care delivery and reduced treatment times, creating favorable conditions for adoption. On-body injectors support streamlined medication administration while enhancing patient convenience. This is contributing to increasing utilization across outpatient settings.
• Growing patient volumes and the continued shift toward same-day care models are further supporting demand. Healthcare facilities are adopting solutions that optimize workflows without compromising treatment quality. On-body injectors help achieve these objectives through efficient delivery of specialty therapies. Consequently, the segment continues to expand steadily.

North America On-body Injector Market

The North America region accounted for 51.3% of the global market in 2025. The market in North America is experiencing robust expansion.

• The market size reached USD 568.7 million in 2025, growing from USD 487.6 million in 2024, and is anticipated to grow at a CAGR of 16.4% from 2026 to 2035.
• The North America market is primarily driven by the growing incidence of chronic conditions, including cancer, diabetes, cardiovascular diseases, and autoimmune disorders. The increasing need for long-term treatment and biologic drug administration has strengthened demand for advanced drug delivery solutions. On-body injectors offer a convenient alternative to frequent hospital-based injections, supporting better treatment adherence.
• According to the Centers for Disease Control and Prevention (CDC), 288,494 new breast cancer cases were reported among females in the United States in 2023, while 43,402 female deaths from breast cancer were recorded in 2024. The significant disease burden continues to increase demand for biologics, targeted therapies, and supportive care treatments, supporting the adoption of on-body injectors for convenient and efficient drug administration across the region.
• The region also benefits from a well-established healthcare infrastructure and high adoption of innovative medical technologies. Pharmaceutical companies are actively developing biologic therapies that require efficient subcutaneous delivery. This has encouraged healthcare providers to integrate on-body injectors into routine treatment protocols.

Europe On-body Injector Market

Europe market accounted for USD 409.2 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• The Europe market is significantly driven by the growing aging population. Elderly individuals are more susceptible to chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions, creating sustained demand for long-term treatment solutions. This demographic trend is increasing the need for patient-friendly drug delivery technologies.
• Healthcare systems across Europe are increasingly prioritizing efficient management of age-related diseases while minimizing hospitalization requirements. On-body injectors support these objectives by enabling convenient administration of specialty therapies. Their ability to improve treatment accessibility is contributing to broader adoption.
• The region's emphasis on patient-centered care and healthcare efficiency is further accelerating market growth. Healthcare providers are increasingly adopting technologies that support independence among elderly patients. This is expected to strengthen demand for on-body injectors throughout the forecast period.

Rest of the World On-body Injector Market

The Rest of the world market is experiencing robust growth over the analysis timeframe.

• The rest of the world market is experiencing steady growth, supported by increasing demand for biologic therapies and ongoing improvements in healthcare accessibility. Rising prevalence of chronic diseases across developing economies is creating a greater need for advanced drug delivery technologies capable of supporting long-term therapeutic management. This is encouraging wider adoption of on-body injectors across diverse healthcare settings.
• The growing shift toward home-based healthcare is further contributing to market expansion. Patients are increasingly seeking convenient treatment options that reduce dependence on hospitals and enable therapy administration in non-clinical environments. On-body injectors support this transition by facilitating self-administration and enhancing treatment continuity, thereby improving the overall patient experience.
• Additionally, increasing preference for minimally invasive treatment solutions and rising awareness of innovative healthcare technologies are supporting market growth. Governments and healthcare providers are investing in healthcare infrastructure and expanding access to advanced therapies across emerging markets. These developments are expected to create favorable opportunities for on-body injector adoption throughout the rest of the world region.

On-body Injector Market Share

• The top five players, Amgen Inc., West Pharmaceutical Services, Inc., Enable Injections, Inc., Ypsomed Holding AG, and Becton, Dickinson and Company (BD), collectively account for approximately 85% of the global market. Their leadership is supported by strong portfolios of on-body injector platforms, wearable drug delivery technologies, and large-volume subcutaneous injection solutions designed for biologics and specialty pharmaceuticals. Furthermore, continuous investments in product innovation, strategic collaborations with pharmaceutical companies, enhancements in dosing accuracy and patient convenience, and expansion of home-based drug delivery capabilities continue to strengthen their competitive position in the market.
• On-body injector manufacturers, drug delivery technology companies, and pharmaceutical partners are increasingly focusing on technological advancements to enhance dosing accuracy, patient comfort, treatment adherence, and ease of administration. Additionally, innovations in programmable delivery systems, large-volume subcutaneous injection technologies, motor-driven platforms, smart connectivity features, and wearable drug delivery solutions are improving the administration of biologics and specialty therapies. Continuous investments in advanced on-body injector technologies, digital health integration, and patient-centric delivery systems are supporting broader adoption across hospitals, homecare settings, and specialty care facilities.
• Market participants, including on-body injector manufacturers, pharmaceutical companies, biotechnology firms, and healthcare providers, are increasingly entering strategic collaborations to accelerate innovation and expand access to advanced drug delivery solutions. Partnerships between device developers and pharmaceutical companies are facilitating the development and commercialization of next-generation on-body injectors designed for biologics, immunotherapies, and other high-value therapeutics. Furthermore, collaborations with digital health companies, research institutions, and healthcare organizations are supporting the development of connected drug delivery platforms, remote patient monitoring capabilities, and enhanced treatment management solutions. These initiatives are strengthening the integration of on-body injectors into routine clinical practice, improving patient convenience and therapy adherence, and contributing to the growing adoption of on-body injector technologies across global healthcare markets.

On-body Injector Market Companies

Few of the prominent players operating in the on-body injector industry include:

• Amgen Inc.
• Becton, Dickinson and Company (BD)
• Eitan Medical
• Enable Injections, Inc.
• Gerresheimer AG
• Insulet Corporation
• Medtronic plc
• Roche Holding AG
• scPharmaceuticals Inc.
• Sensile Medical AG
• Sorrel Medical (LTS Device Technologies)
• Stevanato Group
• Tandem Diabetes Care, Inc.
• West Pharmaceutical Services, Inc.
• Ypsomed Holding AG
   
• West pharmaceuticals services

West Pharmaceutical Services, Inc. plays a significant role in the market by developing advanced drug delivery solutions that support the administration of biologics and specialty pharmaceuticals. The company focuses on improving treatment accessibility and adherence.

• Ypsomed Holding AG

Ypsomed Holding AG is an important contributor to the on-body injector industry, offering patient-centric drug delivery solutions that facilitate self-administration of complex therapies. The company's focus on usability and treatment convenience supports expanding adoption across chronic care applications.

On-body Injector Industry News

• In January 2026, West Pharmaceutical Services, Inc. entered into a definitive agreement with AbbVie to sell the manufacturing and supply rights for its SmartDose On-Body Delivery System. SmartDose is a wearable drug delivery platform designed for the subcutaneous administration of complex injectable therapies, making it a strategic asset for AbbVie as it expands its advanced drug delivery capabilities. This transaction highlights the increasing value of on-body injector technologies and reflects growing pharmaceutical industry investment in patient-centric self-administration solutions.

The on-body injector market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Device type

• Programmable wearable injectors
• Non-programmable wearable injectors

Market, By Usage type

• Disposable wearable injectors
• Reusable wearable injectors

Market, By Technology

• Motor-driven
• Spring-based
• Expanding battery
• Rotary pump
• Other technologies

Market, By Application

• Oncology
• Cardiovascular disease
• Autoimmune disease
• Infectious disease
• Diabetes
• Other applications

Market, By End use

• Hospitals
• Homecare settings
• Specialty clinics & ambulatory surgery centers

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Rest of world